CD307 is a differentiation antigen expressed in B-lineage cells. One soluble and two membrane-bound forms have been predicted and an enzyme-linked immunosorbent assay (ELISA) for soluble CD307 established. Our goal was to determine if CD307 is expressed on the surface of cells from patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and other B-cell malignancies and if soluble CD307 levels are elevated in the blood of patients with these B-cell malignancies. Cells and blood were collected from patients. Expression of CD307 was measured by flow cytometry and blood levels of soluble CD307 by ELISA. High soluble CD307 levels were detected in 21/43 (49%) of patients with MM, 36/46 (78%) with CLL and 9/24 (38%) with MCL. Soluble CD307 levels correlated with plasma cell percentages in bone marrow aspirates in MM and total white blood cells in CLL. CD307 on the cell membrane was detected by flow cytometry in 8/8 MM, 23/29 CLL and 4/5 MCL samples. Because CD307 is present on malignant cells from patients with MM, CLL and MCL, CD307 may be a useful therapeutic target for the treatment of these diseases.
Introduction
A gene family was recently identified that encodes cell surface receptors that are homologous to Fc receptors. [1] [2] [3] [4] [5] [6] The family contains 5-6 members and has several names: immunoglobulin super-family receptor translocation associated (IRTA), Fc receptor homolog (FcRH) or immunoglobulin superfamily-Fc receptor-gp42. The mRNAs for the IRTAs/FcRHs are expressed only in cells of the B-cell linage. The IRTA/FcRH proteins contain cytoplasmic regions with immunoreceptor tyrosine-based activation/ inhibition motifs for possible intracellular signaling. These features suggest that the proteins have a role in regulating B-cell differentiation and function. 1, 7, 8 CD307 (IRTA2/FcRH5), also known as BXMAS1, is a IRTA/ FcRH family member. 1, 3, 6, [8] [9] [10] Based on in situ hybridization studies and reverse transcriptase-polymerase chain reaction analysis of subpopulations of B cells, the CD307 protein is predicted to be expressed in naïve B cells and in a subpopulation of activated B -cells, including memory B cells and plasma cells. 8 IRTAs/FcRHs genes including CD307 gene are located at chromosome 1q21, where translocations and other abnormalities are frequently observed in B-cell non-Hodgkin's lymphoma (B-NHL) and multiple myeloma (MM). This implies that deregulation of transcription of genes at this locus may happen frequently in these diseases. In addition by analogy to other B-cell differentiation antigens, it is anticipated that CD307 will be present on some B-cell malignancies.
There are three different alternative splicing products of the IRTA2/FcRH5 gene producing three different proteins (IRTA2a-c 1 ). IRTA2c is the longest isoform containing nine immunoglobulin (Ig)-like domains in the extracellular region followed by a transmembrane region and a cytoplasmic region. IRTA2b is a glycosylphosphatidylinositol-anchored membrane protein in which the first six Ig-like domains are followed by a 32-amino long peptide containing a glycosylphosphatidylinositol attachment signal. The third CD307 protein possesses eight Ig-like domains and is predicted to be a secreted protein (IRTA2a).
We have produced monoclonal antibodies (mAbs) specific to the extracellular domain of IRTA2c. 11 Using some of these mAbs, the cluster differentiation number 307 (CD307) was assigned to IRTA2/FcRH5. 12, 13 We previously reported the presence of CD307 on the surface of human lymphoma cell lines and malignant cells from patients with hairy cell leukemia (HCL). 11 We have developed two sandwich enzyme-linked immunosorbent assays (ELISAs) that can measure the blood levels of the secreted isoform of CD307 (IRTA2a) 14, 15 and used to measure the levels of soluble CD307 protein in the sera of normal humans and in patients with HCL.
14 In this study, we have measured soluble CD307 levels in blood samples and on cells from patients with a variety of common and important hematological malignancies.
Materials and methods

Samples
Human serum samples from 154 donors (age: 18-65 years, 55% male) were obtained from Bioreclamation Inc. (Hicksville, NY, USA). They are all negative for hepatitis B surface antigen (HBS Ag), human acquired immunodeficiency syndrome (HIV-1) Ag and hepatitis C virus (HCV). We also obtained serum samples of 39 healthy volunteers from Dr Alan T Remaly (Department of Laboratory Medicine, Clinical Center, National Institutes of Health). The normal serum samples included those used in the establishment of the ELISAs. 14 We obtained serum, plasma or cell samples from patients with various hematological malignancies. All samples were obtained through protocols approved by the investigators' review boards of the co-authors of this paper. Samples were drawn from patients with advanced disease requiring therapy, although the tumor burden varied. Serum or plasma samples were obtained from 46 patients with chronic lymphocytic leukemia (CLL) (18 sera and 28 plasmas; median and range of white blood cell count/ml were 65 000 and 2600-388 000), 43 patients with MM (37 sera and six plasmas; median and range of % plasma cells in bone marrow aspirates were 38 and 4-98), 24 patients with mantle cell lymphoma (MCL) (24 sera; 21 patients with stage IV disease, one with stage II, two with unknown stage), 17 patients with diffuse large B-cell lymphoma (DLBCL) (17 sera; nine patients with stage IV disease, three with stage III, three with stage II and two with stage I), 14 patients with acute lymphoblastic leukemia (ALL) (14 sera; nine and four patients with high and moderate disease burden, one with unknown disease status), 11 patients with Hodgkin's lymphoma (HL) (11 sera), 10 patients acute myelogenous leukemia (AML) (10 sera), 10 patients with chronic myelogenous leukemia (CML) (10 sera) and 10 patients with human immunodeficiency virus-associated lymphoma (HIV-L) (nine sera and one plasma; seven patients with stage IV disease, three with stage III). For some CLL and MCL patients, we obtained and analyzed time course samples before and after appropriate treatment. Serum and plasma samples were stored at À801C until the day of use. Cell samples were isolated from blood, lymph node or bone marrow and analyzed within 24 h.
ELISA
A sandwich ELISA using anti-CD307 mAbs, F1 and F25, was employed to measure soluble CD307 in both the serum and plasma samples as described previously.
14 The ELISA is compatible with plasma samples containing heparin as well as serum samples (data not shown). In the ELISA, a CD307-Fc fusion protein is used for calibration. 11 The cutoff value for the normal level of soluble CD307 is the 97.5 percentile of the value from 193 normal donors as recommended by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). 16 Confidence intervals of the reference limits were evaluated by a bootstrap method. 17 
Statistics
The differences of soluble CD307 levels between different groups were examined by the Mann-Whitney nonparametric, unpaired, two-tailed test. The small numbers of samples with non-detectable levels of CD307 were considered to contain 15 ng/ml of CD307 (half of the functional quantitation limit). 18 The correlation between soluble CD307 level and white blood cell counts in CLL patients or plasma cell percentages in bone marrow in MM patients were assessed by Pearson's correlation coefficients (r). All the statistical calculations were carried out using CBstat (AACC, Washington, DC) or statistiXL software (USA Share-it, Inc., Eden Prairie, MN, USA).
Flow cytometric immunophenotyping analysis
Cells isolated from blood, lymph node or bone marrow of the patients with CLL, MM, MCL or ALL were stained within 24 h of collection. The cells were stained with a panel of antibodies as previously described. 19 In specimens from patients with MM, aliquots of cells were permeabilized post cell surface staining and before staining with anti-kappa and anti-lambda goat polyclonal antibody reagents (BD biosciences, San Jose, CA, USA) using the Fix and Perm Cell Permeabilization kit (Caltag Laboratories, Burlingame, CA, USA) according to manufacturer's specifications. The antibody panels were chosen based upon the number of cells, previous histological diagnosis and available clinical history. Cells were stained with a cocktail of antibodies containing anti-CD307 F56-PE 11 and other diseasespecific antibodies that in combination detect the malignant cells. Normal cells within the specimens were analyzed as controls (internal controls). Four-color cytometry was performed with a BD FACSCalibur flow cytometer (Becton-Dickinson, San Jose, CA, USA). CD307 expression was analyzed on the CD19-, CD20-and CD10-positive cells in ALL (confirmed surface light chain negative) and the CD19-, CD20-and CD5-positive cells (confirmed monoclonal) in CLL and MCL. For five of eight patients with MM, CD307 expression was analyzed on CD45 dim to negative, CD38 bright, CD138 positive and monoclonal intracellular light chains positive cells. For the rest of MM samples (3/8), the malignant cells were purified using anti-CD138 microbeads (Miltenyi Biotec, Auburn, CA, USA) and CD307 expression was analyzed on CD138-positive separated cells.
Results and discussion
The soluble CD307 protein levels in the serum or plasma of patients with a variety of B-cell and other hematologic malignancies were measured using a CD307-specific ELISA. The samples were obtained when the patients had a significant disease burden. The levels of CD307 from patients with CLL, MM and MCL and from normal controls are plotted in Figure 1 . The range of soluble CD307 levels in normal controls is o30-600 ng/ml with a median of 188 ng/ml. To determine the cutoff value, we used the 97.5th percentile value of 193 serum samples from normal donors as recommended by the IFCC. 16 The value is 498 ng/ml with 90% confidence limits of 437 and 559 ng/ml. There is no correlation of the soluble CD307 levels with age or with sex of the donors.
14 Soluble CD307 levels are not likely to be substantially affected by inflammation, because elevation of soluble CD307 levels was not observed in the blood of patients with autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus and various dermatological diseases; our unpublished data). Elevations of soluble CD307 levels were detected in 78% of CLL patients, 49% of MM patients and 38% of MCL patients (Figure 1) . Table 1 summarizes the results of ELISA measurements and includes some other diseases. Statistically significant elevations (Po0.01) of soluble CD307 levels were observed in CLL, MM, MCL and HIV-L. Besides the remarkable elevation of soluble CD307 levels, a rank statistics analysis disclosed significant decreases of CD307 level in DLBCL, ALL, HL, AML, although the number of patients with these disease is relatively small compared to CLL, MM or MCL. The basis of this decrease has not been investigated but could be due to chemotherapymediated destruction of normal B cells, which make soluble CD307 or due to invasion of lymph nodes and bone marrow by CD307-negative tumor cells.
To examine the correlation of soluble CD307 levels to tumor burden in CLL and MM, soluble CD307 levels were plotted against white blood cell (WBC) counts in CLL or against plasma cell percentages (% PC) in bone marrow aspirates in MM. As shown in Figure 2a , soluble CD307 levels in CLL patients were well correlated with total WBC, a good indicator for the total malignant cell number in the circulation. The Pearson's correlation coefficient (r) between the log-converted values of the soluble CD307 and WBC is 0.659 (Po0.001). As shown in Figure 2b , soluble CD307 levels in MM patients correlated with the % PC in the bone marrow, an indicator of tumor burden in MM (r ¼ 0.476, Po0.01). The correlation of white cell counts with the soluble CD307 level strongly suggests that soluble CD307 is produced by the malignant cells.
We also analyzed the expression of membrane CD307 on malignant cells by flow cytometric immunophenotyping (FCI) using anti-CD307 mAb F56. 11, 13 Table 2 summarizes the FCI results of cells from patients' blood, bone marrow and lymph node samples. The malignant cells were identified by a unique set of surface makers as described in the Materials and methods section and the presence of CD307 on the malignant cells was determined according to the staining intensity. As shown in Table 2 , the malignant cells in 23 of 29 CLL, eight of eight MM and four of five MCL patients expressed CD307 on the cell surface. In contrast, there was no membrane CD307 detected on the surface of ALL cells. Because previous reports suggested that CD307 is expressed only in subsets of B-cell lineage cells [1] [2] 8 and because only 10-40% of normal B cells (CD19 þ ) in the blood from healthy donors showed a dimly positive anti-CD307 staining (our unpublished data), the high frequency of CD307 expression on the malignant cells could be useful for the diagnosis and treatment of these diseases. The frequency of CD307 expression on malignant cell surface was a little higher than the frequency of elevation of soluble CD307 levels measured by ELISA (Tables 1 and 2 ). This is probably because the disease burden varied widely among the patient groups we analyzed. For example, in CLL patients, the malignant cell numbers vary over 100-fold (Figure 2a) . The FCI data only show the presence of CD307 expression regardless of the total number of malignant cells. The correlation we found between soluble CD307 level and disease burden in CLL and MM (Figure 2) indicates that CD307 is frequently produced by malignant cells in these diseases. Figure 3 shows examples of FCI analysis of patient samples. In Figure 3a , the CLL cells in blood identified as CD19 þ /CD5 þ double positive population, which were stained with an anti-CD307 mAb, F56. In Figure 3b , MCL cells in blood were identified as the CD5 þ /CD19 þ population and stained as CD20 þ /CD307 þ . In Figure 3c , MM cells in bone marrow Table 1 Summary of ELISA measurements of soluble CD307 in serum and plasma samples from patients with various hematological malignancies Soluble CD307 level in the samples (human serum or plasma) were measured by the ELISA (the detection limit ¼ 30 ng/ml). For the statistical evaluation, small numbers of non-detects were substituted by 15 ng/ml (half of the detection limit). To determine positive/negative, 97.5th percentiles for the normal sera (498 ng/ml) were used as the upper reference interval. The 90% confidence limits of the 97.5th percentile are 437 and 559 ng/ml. Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; DLBCL, diffuse large B-cell lymphoma; ELISA, enzyme-linked immunosorbent assay; HIV-L, HIV-associated lymphoma; HL, Hodgkin's lymphoma; MM, multiple myeloma; MCL, mantle cell lymphoma. *Significance of the difference of soluble CD307 level between groups was assessed by Mann-Whitney non-parametric assay. CD307 elevation in hematological malignancies T Ise et al aspirate were identified as CD38 þ /CD45À to dim population in the dot blot; the cells were also positive for CD138 (data not shown). The MM cells expressed lambda light chain (solid line, right-top histogram of Figure 3c ), but did not express kappa light chain (dotted line), which also demonstrates no nonspecific binding of the goat antibody to the cells. The MM cells were stained by the anti-CD307 mAb and not by an isotype control (right-bottom histogram of Figure 3c ).
To determine if soluble CD307 levels changed when the tumor burden was decreased by therapy, we measured soluble CD307 levels in patients with CLL and MCL before and after treatment. In Figure 4a , the levels of soluble CD307 in 18 patients with CLL were monitored for 3-37 months from the start of the treatment. After treatment, the CD307 levels were reduced to normal or below normal in 13/18 (72%) of the CLL patients in agreement with the significant decrease of the WBC. As shown in Figure 4b , the soluble CD307 levels of the MCL patients also decreased after treatment in agreement with the remission of disease. In this study, we found that cells from patients with CLL, MM and MCL express a membrane-bound form of CD307 on their surface. They also frequently have elevated levels of soluble CD307 in their blood that is released by these cells. The elevation of soluble CD307 was associated with tumor burden in CLL and MM and fell after treatment. Overall, the results show that CD307 is expressed on malignant cells in these diseases and can be a new specific marker and potential immunotherapy target. It has already been shown that rituximab is effective in the treatment of CLL 20 and MCL, 21 but there is no effective antibody based therapy for MM. The finding that all eight MM samples examined express CD307 indicates that CD307 should be explored as a therapeutic target in this disease as well as in CLL and MCL. If the antibody is used for therapy, soluble CD307 could bind to the antibody and diminish binding to membrane-bound CD307. However, it should be possible to saturate all the soluble CD307 by an excess of antibody. It might also be possible to isolate antibodies that are specific for the membrane-bound form of CD307 as has been done for CD30. 22 Although the immunoregulatory function of CD307 is not yet established, the presence of immunoreceptor tyrosine-based activation/inhibition intracellular signaling motifs and its restricted expression on certain stages of B cells in the course of antigen-dependent adaptive immunity suggests that it has a function as an immune modulating co-receptor on B cells. As the great diversity seen in hematological malignancies is considered to be a reflection of the complexity of normal hematopoiesis including B-cell development, [23] [24] [25] certain B-cell malignancies are expected to retain CD307 expression comparable to the original B-cell lineages from which the malignant cells are derived. Retention of surface markers is often observed in malignancies with other differentiation antigens. Another possibility is that the 1q21 chromosome abnormality frequently observed in B-NHL and MM may be involved in the deregulation of transcription of the CD307 gene located on 1q21. Our results show that malignant cells of CLL, MM and MCL produce soluble CD307 proteins in the circulation above the normal level in donors without malignancies. All these malignancies are derived from B-cell lineages. Measuring the level of CD307 protein in the serum may be useful for classifying, monitoring and predicting prognosis of these diseases. Also, a high level of CD307 might be associated with the pathogenesis of these diseases.
In summary, we have shown that soluble CD307 is elevated in the blood of patients with CLL, MM and MCL, and that there is a correlation of CD307 levels in the blood with tumor burden. We also demonstrated that CD307 is present on the cell membrane of malignant cells. These findings indicate that CD307 may be a useful therapeutic target for immunotherapy as well as a marker to follow the response to therapy. Figure 4 Soluble CD307 levels with the treatment course of CLL and MCL patients. (a) Eighteen CLL patients who showed elevation of soluble CD307 levels before treatment were tested 3-40 months (average 16 months) after various therapies. Soluble CD307 levels and white blood cell counts on the sampling days are shown. Treatments: Pt1, F þ R; Pt2, F; Pt3, F þ R; Pt4, HDMP þ R; Pt5, F þ R; Pt6, F þ Ca; Pt7, Cl þ R, HDMP þ R; Pt8, CHOP þ R; Pt9, F þ GM-CSF; Pt10, FCR (F þ Cy þ R); Pt11, autologous BM transplant; Pt12, Ca; Pt13, Cl þ R þ P; Pt14, F þ Cy þ R; Pt15, Ca; Pt16, HDMP þ R; Pt17, F þ HDMP þ R; Pt18, glucocorticoids þ HDMP þ R. Abbreviations are HDMP, methylprednisolone; F, fludarabine; R, rituximab; Cy, cyclophosphamide; Ca, campath; P, prednisolone; Cl, Chlorambucil. Complete remission (CR) was recorded in Pt1 and Pt7. Partial remission (PR) was observed in Pt4 and Pt6. (b) Seven MCL patients who showed elevation of soluble CD307 levels before treatment were measured again 3 months after the initiation of various treatments. The disease stage and responses are shown with each patient; CR, complete remission. A few measurements given under the detection limit (30 ng/ml) level of the soluble CD307 are shown in bars with 15 ng/ml of height.
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